This site is intended for Healthcare professionals only.

FDA approves Rigel Pharmaceuticals drug for rare bleeding disorder


FDA approves Rigel Pharmaceuticals drug for rare bleeding disorder

The U.S. Food and Drug Administration (FDA) on Tuesday approved Rigel Pharmaceuticals Inc’s treatment for a rare bleeding disorder.

Rigel’s Tavalisse was approved to treat patients with immune thrombocytopenic purpura, a disease characterized by excessive bruising and bleeding caused by unusually low levels of platelets, which are integral to clotting.

(Reporting by Tamara Mathias in Bengaluru; Editing by Anil D’Silva)



Source: REUTERS
0 comment(s) on FDA approves Rigel Pharmaceuticals drug for rare bleeding disorder

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted